Dodion P, Rozencweig M, Nicaise C, Piccart M, Cumps E, Crespeigne N, Kisner D, Kenis Y
Eur J Cancer Clin Oncol. 1982 Jun;18(6):519-22. doi: 10.1016/0277-5379(82)90220-6.
Twenty-three patients with advanced solid tumors received 9-hydroxy-2N-methyl-ellipticinium acetate at a single daily i.v. dose of 15-80 mg/m2 for 5 consecutive days, repeated every 3 weeks. One partial and one minor response were achieved in two patients with breast cancer. Dryness of the mouth was dose-related and dose-limiting. Local phlebitis was also dose-related and frequently severe at the highest dose levels. Other non-hematologic toxic effects were essentially mild to moderate and included nausea, vomiting, diarrhea, stomatitis, fever, weakness, transient renal and hepatic impairment, alopecia and chest pain. Minimal myelosuppression was encountered. It appears that 60 mg/m2/day is the maximum tolerated dose with a five-day schedule. According to our findings, this schedule does not seem to offer any advantage over the previously tested weekly administrations.
23例晚期实体瘤患者接受了醋酸9-羟基-2N-甲基玫瑰树碱治疗，静脉注射，每日单次剂量为15-80mg/m²，连续5天，每3周重复一次。两名乳腺癌患者中，一名出现部分缓解，一名出现轻度缓解。口干与剂量相关且为剂量限制性毒性。局部静脉炎也与剂量相关，在最高剂量水平时通常较为严重。其他非血液学毒性反应基本为轻度至中度，包括恶心、呕吐、腹泻、口腔炎、发热、乏力、短暂的肾和肝功能损害、脱发及胸痛。骨髓抑制轻微。似乎60mg/m²/天是5天给药方案的最大耐受剂量。根据我们的研究结果，该给药方案与之前测试的每周给药方案相比似乎没有任何优势。
